Skip to main content

New England Journal of Medicine

Endocrinology

Intravenous Levothyroxine for Unstable Brain-Dead Heart Donors.

Last Revised:
PMID: 38048188
DOI: 10.1056/NEJMoa2305969

Summary

A US-based study involving 15 organ-procurement organizations and 838 brain-dead donors found no significant difference in heart transplant outcomes between donors given an infusion of intravenous levothyroxine and those given a saline infusion. The occurrence of severe hypertension and tachycardia was higher in the levothyroxine group.

Key Takeaways

  • Intravenous levothyroxine infusion in hemodynamically unstable, brain-dead potential heart donors did not lead to significantly more successful heart transplants compared to saline infusion.
  • The levothyroxine treatment did not show any substantial differences in weaning from vasopressor therapy, ejection fraction on echocardiography, or the number of organs transplanted per donor.
  • The levothyroxine group experienced more cases of severe hypertension and tachycardia compared to the saline group.

Latest Articles in Endocrinology

Authors

Rajat Dhar, Gary F Marklin, W Dean Klinkenberg, Jinli Wang, Charles W Goss, Abhijit V Lele, Clark D Kensinger, Paul A Lange, Daniel J Lebovitz

Full Abstract

  • BACKGROUND: Hemodynamic instability and myocardial dysfunction are major factors preventing the transplantation of hearts from organ donors after brain death. Intravenous levothyroxine is widely used in donor care, on the basis of observational data suggesting that more organs may be transplanted from donors who receive hormonal supplementation.
  • METHODS: In this trial involving 15 organ-procurement organizations in the United States, we randomly assigned hemodynamically unstable potential heart donors within 24 hours after declaration of death according to neurologic criteria to open-label infusion of intravenous levothyroxine (30 μg per hour for a minimum of 12 hours) or saline placebo. The primary outcome was transplantation of the donor heart; graft survival at 30 days after transplantation was a prespecified recipient safety outcome. Secondary outcomes included weaning from vasopressor therapy, donor ejection fraction, and number of organs transplanted per donor.
  • RESULTS: Of the 852 brain-dead donors who underwent randomization, 838 were included in the primary analysis: 419 in the levothyroxine group and 419 in the saline group. Hearts were transplanted from 230 donors (54.9%) in the levothyroxine group and 223 (53.2%) in the saline group (adjusted risk ratio, 1.01; 95% confidence interval [CI], 0.97 to 1.07; P = 0.57). Graft survival at 30 days occurred in 224 hearts (97.4%) transplanted from donors assigned to receive levothyroxine and 213 hearts (95.5%) transplanted from donors assigned to receive saline (difference, 1.9 percentage points; 95% CI, -2.3 to 6.0; P<0.001 for noninferiority at a margin of 6 percentage points). There were no substantial between-group differences in weaning from vasopressor therapy, ejection fraction on echocardiography, or organs transplanted per donor, but more cases of severe hypertension and tachycardia occurred in the levothyroxine group than in the saline group.
  • CONCLUSIONS: In hemodynamically unstable brain-dead potential heart donors, intravenous levothyroxine infusion did not result in significantly more hearts being transplanted than saline infusion. (Funded by Mid-America Transplant and others; ClinicalTrials.gov number, NCT04415658.).

Tags

Please note that the article summaries provided in this content are generated by a large language model AI system and may contain errors or omissions. While we strive to provide accurate and helpful information, we cannot guarantee the correctness or completeness of the summaries. We encourage readers to refer to the original source material for complete and accurate information.